Kornimate/medical-research-clean huggingface dataset:
precision medicine for prediction & prevention of early pre-eclampsia

Conditions: Pre-Eclampsia

Summary: this study aims to evaluate the feasibility of implementing a clinical model for precision screening of early pre-eclampsia into the current prenatal screening service at sunnybrook health sciences center (shsc).

pre-eclampsia (pe) represents a pregnancy-specific systemic disorder that affects 3-8% of all pregnancies. in developed countries pe is considered a major public health problem responsible for severe maternal complications such as coagulopathy, renal and liver failure, stroke, and maternal death (\>76,000 maternal death annually). the traditional approach to screening for preeclampsia endorsed by national guidelines is based on a combination of maternal characteristics along with medical, obstetric and family history. however, although these methods are simple and easy to perform, maternal factors can only identify less than 35% of all preeclampsia and approximately 40% of preterm-preeclampsia at a false- positive rate of 10%. more recently, multivariate analysis has been used to develop predictive models for preeclampsia that can be applied as early as 11-13+6 weeks gestation. one such algorithm, developed by the fetal medicine foundation uk(mfm uk), incorporates maternal risk factors, uterine artery doppler, mean arterial pressure, and serum markers of placental function and placental growth factor. the fmfuk algorithm has been shown to predict approximately 75-90% of those women destined to develop preeclampsia prior to 37 and 34 weeks respectively, at a false positive rate of 10%. this algorithm has been validated prospectively in several studies, including the prediction of other placental mediated complications of pregnancy, such as fetal growth restriction and perinatal death. the new clinical model will include the following additions to the existing first trimester screening for aneuploidy: * additional clinical history * blood pressure measurements * ultrasound for uterine artery doppler measurements * expanded prenatal screening requisition * quality assurance training of ultrasound technicians for the uterine artery doppler measurements * fetal medicine foundation validated risk calculation algorithm * communicate results of the risk calculation algorithm from nygh to shsc and participant health care providers. while the ultimate goal will be to scale up and adapt this new clinical model, this protocol focuses on the feasibility of implementing the new clinical model at a single centre, sunnybrook health sciences centre.

Eligibility criteria:
inclusion criteria: 1. women with a singleton pregnancy \> 18 years old 2. not on low dose aspirin 3. carrying a live fetus with crown rump length (crl) between 41 and 84mm 4. able to provide informed consent 5. having a nuchal translucency ultrasound exclusion criteria: 1. women with a singleton pregnancy \< 18 years old 2. women currently taking low dose aspirin 3. women declining a nuchal translucency ultrasound 4. women unable to provide informed consent 5. women with a multiple pregnancy 6. women with a demised fetus or a crl \ 84mm
robotic bronchoscopy with cone ct and indocyanine green to aid removal of lung lesions in patients with stage i non-small cell lung cancer or lung metastases, replacing study

Conditions: Lung Non-Small Cell Carcinoma; Metastatic Malignant Neoplasm in the Lung; Stage I Lung Cancer AJCC v8

Summary: this phase ii trial studies the use of ion robotic bronchoscope with a mobile computed tomography (ct) scanner to biopsy tumors and inject a fluorescent dye called indocyanine green to mark the tumor during surgery in patients with stage i non-small cell lung cancer or cancer that has spread to the lung (lung metastases). sometimes small tumors or those that are not on the surface of the lung can be challenging to remove without making larger incisions. injecting the dye, may help doctors see the tumor more easily, which may allow for smaller incisions and by being able to see the tumor, doctors may be better able to decide where to make the incisions in order to get all of the tumor out.

primary objective: i. to evaluate the feasibility of using the ion endoluminal platform (iep; intuitive, sunnyvale, california \[ca\]) with the cios spin - a mobile cone-beam c - (siemens medical solutions, malvern, pennsylvania \[pa\], united states \[us\]) in the operating room setting. outline: during standard of care surgical resection, patients undergo robotic bronchoscopy and ct. patients also receive indocyanine green via injection.

Eligibility criteria:
inclusion criteria: * age 18-80 years * medically operable * undergoing pulmonary resection for either stage i non-small cell lung cancer (nsclc) (undergoing segmentectomy) or metastatic disease to the lung * lesions \< 2cm in longest diameter * lesions are located at least 1cm from the pleura exclusion criteria: * pregnant * serum creatinine \> 2.0 * central lesions * iodide allergy
carboplatin and paclitaxel in elderly women with newly diagnosed ovarian, peritoneal, or fallopian cancer

Conditions: Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer; Mixed Tumor, Mesodermal

Summary: the main purpose of this trial is to look at how elderly women (70 years of age or older) with newly diagnosed ovarian, peritoneal, or fallopian tube cancer manage six cycles of carboplatin and paclitaxel, what side effects they experience, and how their cancer reacts or responds to standard carboplatin and paclitaxel chemotherapy.

objectives: primary •to determine the completion rate of six cycles of carboplatin/paclitaxel with no dose reductions because of toxicities. secondary * assess cancer antigen 125 (ca125) response rates of paclitaxel/carboplatin in this group of patients * assess significant toxicities in this group of patients and compare to a non-elderly population. * to determine which clinical parameters will predict lack of completion of six cycles of carboplatin and paclitaxel chemotherapy. * assess quality of life changes during chemotherapy and up to one year after completion of chemotherapy. * assess progression-free survival and overall survival for this group. * to determine the feasibility of accrual. statistical design: using a one sample binomial design, with 37 patients there was 83% power to detect a null hypothesis of a 45% therapy completion rate versus an alternative hypothesis of a 66% rate assuming a one-sided 5% alpha. the regimen would be declared ineffective if there were 19 or fewer patients who completed 6 cycles of carboplatin and paclitaxel chemotherapy without dose adjustments.

Eligibility criteria:
inclusion criteria: * age 70 or older * eastern cooperative oncology group (ecog) performance status of 0,1 or 2 and is medically eligible and clinically appropriate to receive systemic chemotherapy * diagnosis of ovarian, primary peritoneal, fallopian tube cancer, papillary serous cancer of the endometrium, or mixed mesodermal tumors of the ovary, fallopian tube or uterus * life expectancy greater than 6 months * baseline laboratory values as described in protocol exclusion criteria: * active infection requiring antibiotics at the time of starting chemotherapy * prior pelvic radiotherapy \> 25% of bone marrow * any uncontrolled medical problem that in the opinion of the investigator would preclude safe administration of the study drugs * past history of bone marrow transplantation or stem cell support * known history of central nervous system (cns) metastasis * history of prior malignancy that required prior systemic therapy * clinically significant cardiac disease * uncontrolled diabetes mellitus * any signs of intestinal obstruction * participation in an investigational drug study within three weeks prior to study entry * history of psychiatric disability or other central nervous system disorder

Keywords: carboplatin paclitaxel elderly women
comparative study for medical therapy for lower ureteral stones

Conditions: Lower Ureteral Stones

Summary: the goal of this clinical trial is to compare the efficacy and adverse effects of different drugs as a medical expulsive therapy for lower ureteral stones. the main questions it aims to answer are: * which of the following are more effective silodosin, tamsulosin, silodosin plus tadalafil and tamsulosin plus tadalafil as a therapy for lower ureteral stones? * what medical problems do participants have when taking these drugs? researchers will compare silodosin, tamsulosin, silodosin plus tadalafil and tamsulosin plus tadalafil to see which drug works better to treat lower ureteral stones participants will: * take silodosin, tamsulosin, silodosin plus tadalafil or tamsulosin plus tadalafil every day for 28 days * visit the clinic once every 2 weeks for checkups and tests * keep a diary of their symptoms.


Eligibility criteria:
inclusion criteria: * inclusion criteria were adult patients aged 18 years and older with lower ureteral stones measuring 5-10 mm in diameter, diagnosed through imaging techniques such as kidney-ureter-bladder (kub) x-rays or computed tomography (ct) scans. exclusion criteria: * exclusion criteria included pregnant and lactating women, renal insufficiency, congenital urinary tract abnormalities, associated kidney stones or contralateral ureteric stones, solitary kidneys, associated infected stones, uncontrolled pain, severe hydronephrosis, history of allergy to the study medications and recent treatment for ureteral stones within the past 3 months (e.g., lithotripsy or surgery) .
transcriptomic analysis of incisional hernia based on high-throughput sequencing technology

Conditions: Incisional Hernia; Extracellular Matrix Alteration

Summary: this study included patients who underwent surgical treatment for incisional hernia and non-hernia conditions. surgical specimens were collected for transcriptome sequencing to obtain the gene expression list. then genes analyzed by gene ontology, protein interactions, and signaling pathway enrichment using the expression matrix.


Eligibility criteria:
inclusion criteria: 1.18 to 75 years 2.diagnosed with incisional hernia 3.normal tumour markers 4.elective surgery patients. exclusion criteria: 1. patients with vital organ failure (heart liver, lung, kidney and others) 2. malignant tumors not been completely relieved by active treatment, 3. patients who have psychiatric diseases or comprehension disorders. 4. patients with metabolic disease involving connective tissue collagen.
effect of pioglitazone on inflammation in cystic fibrosis

Conditions: Cystic Fibrosis

Summary: the purpose of this study is to determine the effect of pioglitazone on reducing airway inflammation in cystic fibrosis and characterize the amount and timecourse of pioglitazone elimination from the body.

progressive loss of lung function due to chronic infection and inflammation is the primary cause of morbidity and mortality in patients with cf. current therapies directed at treatment of chronic p. aeruginosa infection (e.g. aerosolized tobramycin, azithromycin) provide short-term improvement in pulmonary function; however, persistence of the infection/inflammation causes the inevitable loss of lung function. ppargamma is a nuclear transcription factor which is known to reduce activation of nfkb, a central mediator of airway inflammation in cf. recent studies demonstrate that ppargamma expression is reduced in patients with cf and may offer a potential therapeutic target to combat airway inflammation in cf. pioglitazone is a thiazolidinedione whose principal pharmacological target it ppargamma. the purpose of this pilot study is to determine the pharmacokinetics/pharmacodynamics of pioglitazone and effect on reducing airway inflammation in cystic fibrosis.

Eligibility criteria:
inclusion criteria: * age greater than 18 years * clinically stable (fev1 within 10% of baseline) * fev1 \> 40% predicted exclusion criteria: * history of hypoglycemic events * hepatic disease (ast, alt \> 2.5x uln) * renal disease (gfr \< 60 ml/min - 1.73m2) * currently receiving beta-blocker, oral corticosteroids, statin, angiotensin receptor blocker, trimethoprim-sulfamethoxazole, gemfibrozil, or rifampin therapies. * allergy to thiazolidinediones * pregnancy or attempting to conceive, breast feeding * hematocrit \< 30 * congestive heart failure * pulmonary hypertension
assessment of hbv vaccine immunity after 18 years

Conditions: Hepatitis b Vaccine

Summary: the purpose of this study is to assess hbv immunity and institute policy regarding the hepatitis b vaccination practices in the idf among a cohort that was vaccinated during infancy.

the study population will consist of both males and females who were born after january 1st 1992, who are in medical training at the medical corps training base. demographic information will be obtained through a questionnaire given to the soldiers in the study , as well as the idf computerized personnel information database. this study is designed to determine hbv vaccination policy among new hcws in the idf, who were vaccinated during infancy. this population was recruited to the idf since the second half of 2010. therefore, it is necessary to conduct this study on new hcws that will be receiving the routine hbv vaccination and that will be at risk for hbv infection in the future due to their occupation in the army (hcws, etc).

Eligibility criteria:
inclusion criteria: 1. soldiers born on or after january 1st, 1992 2. soldiers taking part in a medical training course 3. soldiers that signed an informed consent form exclusion criteria: 1. born before january 1st, 1992 2. soldiers with previous known infection with hbv 3. soldiers with documented evidence of immunity against hbv 4. soldiers that refuse to participate in the study
minimal invasive tlif arthrodesis using augmented reality navigation for percutaneous pedicle aiming

Conditions: Arthrosis

Summary: surgery for degenerative spondylolisthesis requires decompression of the narrow lumbar canal and fixation by osteosynthesis-arthrodesis. conventional surgery is done through the open route. for 10-15 years, minimally invasive techniques have been established, allowing faster postoperative recovery for the patient. the downside to these techniques is the use of intraoperative fluoroscopy. this is why surgical navigation systems have been developed, allowing safe positioning of implants (pedicle screws). a new process (augmented reality navigation) has been tested in vitro and applied in open surgery. the hus were the first establishment to apply this new method in minimally invasive surgery in a hybrid room of surgery and interventional radiology.


Eligibility criteria:
inclusion criteria: * major subject (≥18 years old) * subject operated at the hus between march and december 2019 * subject with a surgical indication for arthrodesis and decompression of the lumbar canal for degenerative spondylolisthesis l3-l4 or l4-l5 * subject not having expressed his opposition, after information, to the reuse of his data for the purposes of this research. exclusion criteria: * subject having expressed opposition to participating in the study * subject under guardianship or guardianship * subject under safeguard of justice

Keywords: arthrosis spondylolisthesis degenerative spondylolisthesis arthrodesis osteosynthesis-arthrodesis fluoroscopy. pedicle screws
coiling of echogenic sciatic nerve perineurial catheters with integral stylet

Conditions: Pain; Trauma

Summary: coiling of perineurial catheters under the sciatic nerve and examination of catheters position through ultrasound imaging 36 hours postoperatively.

to assess procedural effectiveness of the preferred coiling technique (method b), a pilot study was performed. straight perineural catheters with coiled distal ends behind the sciatic nerve were examined in 25 patients who had sustained tibia fractures. patients were placed in the lateral position (with the injured leg uppermost) and a us-guided sciatic nerve block was performed under aseptic conditions. the sciatic nerve was visualized at the upper third of the posterior thigh (short axis view) and a tuohy needle (21 g × 10 mm, sonolong/nanoline, pajunk, germany) was inserted in a lateral to medial direction. the needle was placed underneath the sciatic nerve and 10 ml of ropivacaine (0.1%) were injected. a perineural catheter (with retracted integral stylet by 6 cm) (sonolong sono, pajunk, germany) was then threaded through the needle tip and coiled behind the sciatic nerve. confirmation of correct catheter tip placement was defined as adequate spread and contact of ropivacaine injectate (3 ml, 0.1%) with the sciatic nerve (figure 2c). if the distribution of the local anaesthetic (la) could not be visualized on the first infusion, 2 additional injections were performed until the distribution was clearly seen. if la spread could not be visually confirmed, or if, when confirmed, la did not come in contact with the sciatic nerve, the case was excluded. subcutaneous tunneling (4 cm long) and placement of a transparent adhesive dressing were used to secure the catheter. all sciatic nerve blocks were followed by an adductor canal block (10 ml of ropivacaine 0.5%) and general anaesthesia. a continuous infusion of ropivacaine (8-12 ml, 0.1%) was commenced and a combination of oxycodone 5 mg with paracetamol 325 mg was provided on an as-needed basis after surgery. all nerve blocks were assessed and data were collected in the post-anaesthetic care unit, and every 12 hours thereafter until 36 hours postoperatively from members of acute pain service (aps) team not participating in the study.

Eligibility criteria:
inclusion criteria: orthopaedic patients with tibia fractures - exclusion criteria: * patients with infection in the sub gluteal region. * allergies to local aesthetics * patients refusal to consent for the nerve block * neurological disorders * pregnancy

Keywords: prineural catheter ultrasound sciatic nerve
two- dimensional speckle tracking echocardiography after primary percutaneous coronary intervention

Conditions: Myocardial Infarction

Summary: st-segment elevation myocardial infarction (stemi) is a major cause of morbidity and mortality worldwide. in spite of decrease in acute and long-term mortality following stemi in parallel with more use of reperfusion therapy, such as primary percutaneous coronary intervention (ppci), modern antithrombotic therapy, and secondary prevention, mortality remains considerable. reduced ef is a well-known predictor of increased short and long term major adverse cardiovascular events mace :( heart failure, stroke and death)


Eligibility criteria:
inclusion criteria: * st elevation myocardial infarction patients after primary percutaneous coronary intervention exclusion criteria: * previous myocardial infarction. * sever or haemodynamically significant (associated with chamber dilation) valvular heart diseases. * previous heart failure. * previous cerebrovascular strokes. * atrial fibrillation. * severe comorbidities as severe renal impairment, hepatic or respiratory failure. * bad equality views which affects accurate speckle tracking imaging.
association of quantitative and functional imaging with clinical outcome after spinal cord injury

Conditions: Spinal Cord Injuries

Summary: the overall study aim is to provide additional magnetic resonance imaging parameters of the cervical spinal cord, brainstem and brain and a better understanding of changes after spinal cord injury (sci) and to define new magnetic resonance (mr) biomarkers to correlate with sensomotoric functioning and clinical outcome.

injury of the spinal cord, for instance induced by trauma, is complex involving primary mechanisms caused by forces directly affecting the spinal cord and secondary mechanisms consisting of complex physiological processes after trauma. conventional magnetic resonance imaging (mri) is the current standard to assess morphologic changes of the spinal cord after injury. however, conventional mri provides little information regarding the health and integrity of the brain and spinal cord tissue itself, due to the fact that signal intensity changes are non-specific and do not correspond directly with physiological processes. this is reflected in the poor correlation of conventional mri data with neurological and functional impairment in various spinal cord pathologies (such as multiple sclerosis compression myelopathy) and failure to provide reliable prognostic information. by applying a combination of diffusion weighted imaging, functional mri and magnetic resonance spectroscopy will give us a better understanding of the changes after injury of the cervical spinal cord, brainstem and brain. correlating the imaging data with the neurological and clinical status of patients could improve the patient status prediction and therapy planning. this study is divided into three sub-projects: i) reproducibility study of the mr measurements in healthy controls ii) progression of mr biomarkers in subacute patients with sci and comparison to chronic patients with sci iii) prediction of clinical outcome based on mr biomarkers

Eligibility criteria:
healthy controls: inclusion criteria: * age between 18 and 80 years * no previous history of severe cervical trauma, traumatic brain injury, cervical surgery or signs of neurological impairment and no known neurological disease. exclusion criteria: * not meeting the mri screening requirements * unable to give consent * unable to fulfill the above mentioned inclusion criteria subacute and chronic patients with spinal cord injury: inclusion criteria: * lesion level at or below c3 * etiology of the spinal cord injury is traumatic or non-traumatic * age between 18 and 80 years * time of trauma or onset of symptoms for subacute sci patients is more than 3 weeks and for the chronic sci patients more than 2 years exclusion criteria: * lesion level below l2 * other known pathology of the spinal cord/brain (e.g. ms) or progressive neurological disorders * inability to meet the mri screening requirements (e.g. pacemaker or other electronic devices), * severe head trauma as defined by a glasgow coma scale (gcs) of \< 14 * patients who are ventilator dependant
spanish decision tool for ovarian cancer maintenance therapy

Conditions: Ovarian Cancer

Summary: to develop a shared decision-making (sdm) tool to help spanish-speaking patients make decisions about their maintenance therapy

objectives: * create a low literacy version of a shared decision-making (sdm) tool for ovarian cancer maintenance therapy for spanish speaking individuals. * to explore the feasibility and acceptability of incorporating the sdm tool into routine clinical care for spanish speaking individuals. * to estimate the effectiveness of the sdm tool on quality of the decision making in patients with ovarian cancer who are making decisions about maintenance therapy through a pilot study.

Eligibility criteria:
study population: this study will enroll patients and clinical providers. inclusion criteria: patients • eligible patients must be: 1) individuals ≥ 18 years with advanced stage high grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are receiving or have completed platinum-based chemotherapy for ovarian cancer and are potentially eligible to receive maintenance therapy; 2) able to understand, speak or read in spanish. exclusion criteria: patients • inability or unwillingness to sign informed consent inclusion criteria: clinicians • eligible clinicians will include: 1) md anderson gynecologic oncologists and advanced practice providers who practice at the houston area locations (hals), md anderson cancer center, or our county safety net hospital, the harris health system (lbj hospital). exclusion criteria: clinicians • inability or unwillingness to sign informed consent